TY  - JOUR
AB  - Radiotherapy represents an effective curative strategy that along with surgery and chemotherapy is traditionally used in cancer treatment. An optimal therapy delivers accurate radiation doses to tumour while protecting surrounding normal tissue. Although radiotherapy regimens have improved in recent years, tumour radioresistance and normal tissue toxicity remain major challenges that considerably contribute to the effectiveness of cancer therapy. These factors affect especially radiosensitive individuals in the treatment of whom the balance between effective tumour killing and adverse normal tissue late effects turns out to be problematic. Understanding molecular mechanisms involved in tumour and normal tissue response is essential in order to improve radiotherapy outcome in the field of personalised medicine. Alteration in the global proteome of cells and tissues truthfully reflects the changes in physiology and pathophysiology of biological samples. This makes proteomics analysis a powerful tool principally enabling identification of radioresistance biomarkers in cancer and sensitivity biomarkers in individuals. Yet, the use of proteomics in cancer therapy is still in its infancy and more research is needed to fulfil the great promise of this technique. The present review summarises recent proteomic-based studies searching for biomarkers for more accurate prediction of radiotherapeutic response in tumour and normal tissue.
AU  - Azimzadeh, O.
AU  - Tapio, S.
C1  - 51632
C2  - 43402
CY  - Sheung Wan
SP  - S779-S788
TI  - Proteomics approaches to investigate cancer radiotherapy outcome: Slow train coming.
JO  - Transl. Cancer Res.
VL  - 6
PB  - Ame Publ Co
PY  - 2017
SN  - 2218-676X
ER  - 

TY  - JOUR
AB  - Radiotherapy (RT) is a widely used and effective non-surgical cancer treatment. However, the mechanism behind several major challenges to efficacy, such as tumor radioresistance, normal tissue toxicity, individual radiation hypersensitivity and promoted metastatic spread, are not fully understood. The involvement of microRNAs (miRNAs) in processes important for tissue radiation responses, including DNA damage repair, activation of signalling cascades or changes to the microenvironment, is being recognized. Most recently, the exchange of miRNAs between irradiated and non-irradiated cells through microvesicles was described as a new component of the cellular radiation response. The therapeutic inhibition or mimicking of miRNAs to overcome radioresistance during therapy, and the usage of miRNAs as predictive biomarkers for therapy response and prognosis, are promising applications of miRNAs in RT. However, due to the lack of in vivo or clinical studies the full potential of miRNAs for RT is difficult to estimate. In summary this contribution gives an overview about new understanding of the miRNA involvement in the radiation response and summarizes first RT-related applications.
AU  - Mörtl, S.
AU  - Mutschelknaus, L.
AU  - Heider, T.
AU  - Atkinson, M.J.
C1  - 50429
C2  - 42213
CY  - Sheung Wan
SP  - S1262-S1269
TI  - MicroRNAs as novel elements in personalized radiotherapy.
JO  - Transl. Cancer Res.
VL  - 5
PB  - Ame Publ Co
PY  - 2016
SN  - 2218-676X
ER  -